Sanofi Asks Trade Agency to Block Spectrum’s Rolontis From U.S.

Sanofi’s Bioverativ filed a U.S. trade complaint seeking to block imports of Spectrum Pharmaceuticals’ proposed Rolontis, a drug used to treat a condition caused by chemotherapy that leaves patients more susceptible to infections.

• Bioverativ and Genzyme claim Spectrum and its South Korean manufacturer, Hanmi Pharmaceutical, infringe a patent that expires in 2028 for what the Sanofi units called an “innovative platform technology” which can prolong the half-lives of biologic-based treatments
• The technology has “wide-ranging applications” and is used by Sanofi in Eloctate and Alprolix, which are used for patients with rare blood disorders, according to the complaint ...